Accueil/Actions/NLSP

NLSP

USD

NLS Pharmaceutics Ltd. Ordinary Shares

$0.762-0.008 (-1.039%)

Prix en Temps Réel

Healthcare

Biotechnologie

Suisse

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché

Fondamentaux de l'Entreprise

Statistiques de Trading

Métriques de Marché

Ouverture

$0.770

Haut

$0.830

Bas

$0.760

Volume

0.00M

Fondamentaux de l'Entreprise

Capitalisation Boursière

4.0M

Industrie

Biotechnologie

Pays

Switzerland

Statistiques de Trading

Volume Moyen

0.07M

Bourse

NCM

Devise

USD

Intervalle sur 52 Semaines

Bas $0.76Actuel $0.762Haut $43.4

Actualités Connexes

30 oct. 2025 · 20:15

PR Newswire

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger

NewcelX Ltd. ("NewcelX" or the "Company") completed the previously announced merger transaction, pursuant to that certain Agreement of Merger and...

NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger

30 oct. 2025 · 11:00

PR Newswire

NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and...

NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs

29 oct. 2025 · 10:00

PR Newswire

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem

29 oct. 2025 · 07:53

PR Newswire

NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem") today announced that,...

NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

27 oct. 2025 · 11:00

PR Newswire

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and...

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies

PR Newswire

23 oct. 2025 · 10:01

NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central...